Ebselen, a small-molecule capsid inhibitor of HIV-1 replication

Suzie Thenin-Houssier, Ian Mitchelle S De Vera, Laura Pedro-Rosa, Angela Brady, Audrey Richard, Briana Konnick, Silvana Opp, Cindy Buffone, Jakob Fuhrmann, Smitha Kota, Blase Billack, Magdalena Pietka-Ottlik, Timothy Tellinghuisen, Hyeryun Choe, Timothy Spicer, Louis Scampavia, Felipe Diaz-Griffero, Douglas J. Kojetin, Susana T. Valentea

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The human immunodeficiency virus type 1 (HIV-1) capsid plays crucial roles in HIV-1 replication and thus represents an excellent drug target. We developed a high-throughput screening method based on a time-resolved fluorescence resonance energy transfer (HTS-TR-FRET) assay, using the C-terminal domain (CTD) of HIV-1 capsid to identify inhibitors of capsid dimerization. This assay was used to screen a library of pharmacologically active compounds, composed of 1,280 in vivo-active drugs, and identified ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one], an organoselenium compound, as an inhibitor of HIV-1 capsid CTD dimerization. Nuclear magnetic resonance (NMR) spectroscopic analysis confirmed the direct interaction of ebselen with the HIV-1 capsid CTD and dimer dissociation when ebselen is in 2-fold molar excess. Electrospray ionization mass spectrometry revealed that ebselen covalently binds the HIV-1 capsid CTD, likely via a selenylsulfide linkage with Cys198 and Cys218. This compound presents anti-HIV activity in single and multiple rounds of infection in permissive cell lines as well as in primary peripheral blood mononuclear cells. Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. This compound also blocks infection of other retroviruses, such as Moloney murine leukemia virus and simian immunodeficiency virus, but displays no inhibitory activity against hepatitis C and influenza viruses. This study reports the use of TR-FRET screening to successfully identify a novel capsid inhibitor, ebselen, validating HIV-1 capsid as a promising target for drug development.

Original languageEnglish (US)
Pages (from-to)2195-2208
Number of pages14
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Capsid
Virus Replication
HIV-1
Dimerization
Organoselenium Compounds
Retroviridae Infections
Pharmaceutical Preparations
High-Throughput Screening Assays
Moloney murine leukemia virus
ebselen
Simian Immunodeficiency Virus
Fluorescence Resonance Energy Transfer
Electrospray Ionization Mass Spectrometry
Life Cycle Stages
Orthomyxoviridae
Hepacivirus
Blood Cells
Magnetic Resonance Spectroscopy
HIV
Cell Line

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Thenin-Houssier, S., De Vera, I. M. S., Pedro-Rosa, L., Brady, A., Richard, A., Konnick, B., ... Valentea, S. T. (2016). Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. Antimicrobial Agents and Chemotherapy, 60(4), 2195-2208. https://doi.org/10.1128/AAC.02574-15

Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. / Thenin-Houssier, Suzie; De Vera, Ian Mitchelle S; Pedro-Rosa, Laura; Brady, Angela; Richard, Audrey; Konnick, Briana; Opp, Silvana; Buffone, Cindy; Fuhrmann, Jakob; Kota, Smitha; Billack, Blase; Pietka-Ottlik, Magdalena; Tellinghuisen, Timothy; Choe, Hyeryun; Spicer, Timothy; Scampavia, Louis; Diaz-Griffero, Felipe; Kojetin, Douglas J.; Valentea, Susana T.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 4, 01.04.2016, p. 2195-2208.

Research output: Contribution to journalArticle

Thenin-Houssier, S, De Vera, IMS, Pedro-Rosa, L, Brady, A, Richard, A, Konnick, B, Opp, S, Buffone, C, Fuhrmann, J, Kota, S, Billack, B, Pietka-Ottlik, M, Tellinghuisen, T, Choe, H, Spicer, T, Scampavia, L, Diaz-Griffero, F, Kojetin, DJ & Valentea, ST 2016, 'Ebselen, a small-molecule capsid inhibitor of HIV-1 replication', Antimicrobial Agents and Chemotherapy, vol. 60, no. 4, pp. 2195-2208. https://doi.org/10.1128/AAC.02574-15
Thenin-Houssier S, De Vera IMS, Pedro-Rosa L, Brady A, Richard A, Konnick B et al. Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. Antimicrobial Agents and Chemotherapy. 2016 Apr 1;60(4):2195-2208. https://doi.org/10.1128/AAC.02574-15
Thenin-Houssier, Suzie ; De Vera, Ian Mitchelle S ; Pedro-Rosa, Laura ; Brady, Angela ; Richard, Audrey ; Konnick, Briana ; Opp, Silvana ; Buffone, Cindy ; Fuhrmann, Jakob ; Kota, Smitha ; Billack, Blase ; Pietka-Ottlik, Magdalena ; Tellinghuisen, Timothy ; Choe, Hyeryun ; Spicer, Timothy ; Scampavia, Louis ; Diaz-Griffero, Felipe ; Kojetin, Douglas J. ; Valentea, Susana T. / Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 4. pp. 2195-2208.
@article{eda83b5166c54d1ba61d16d98b0f8463,
title = "Ebselen, a small-molecule capsid inhibitor of HIV-1 replication",
abstract = "The human immunodeficiency virus type 1 (HIV-1) capsid plays crucial roles in HIV-1 replication and thus represents an excellent drug target. We developed a high-throughput screening method based on a time-resolved fluorescence resonance energy transfer (HTS-TR-FRET) assay, using the C-terminal domain (CTD) of HIV-1 capsid to identify inhibitors of capsid dimerization. This assay was used to screen a library of pharmacologically active compounds, composed of 1,280 in vivo-active drugs, and identified ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one], an organoselenium compound, as an inhibitor of HIV-1 capsid CTD dimerization. Nuclear magnetic resonance (NMR) spectroscopic analysis confirmed the direct interaction of ebselen with the HIV-1 capsid CTD and dimer dissociation when ebselen is in 2-fold molar excess. Electrospray ionization mass spectrometry revealed that ebselen covalently binds the HIV-1 capsid CTD, likely via a selenylsulfide linkage with Cys198 and Cys218. This compound presents anti-HIV activity in single and multiple rounds of infection in permissive cell lines as well as in primary peripheral blood mononuclear cells. Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. This compound also blocks infection of other retroviruses, such as Moloney murine leukemia virus and simian immunodeficiency virus, but displays no inhibitory activity against hepatitis C and influenza viruses. This study reports the use of TR-FRET screening to successfully identify a novel capsid inhibitor, ebselen, validating HIV-1 capsid as a promising target for drug development.",
author = "Suzie Thenin-Houssier and {De Vera}, {Ian Mitchelle S} and Laura Pedro-Rosa and Angela Brady and Audrey Richard and Briana Konnick and Silvana Opp and Cindy Buffone and Jakob Fuhrmann and Smitha Kota and Blase Billack and Magdalena Pietka-Ottlik and Timothy Tellinghuisen and Hyeryun Choe and Timothy Spicer and Louis Scampavia and Felipe Diaz-Griffero and Kojetin, {Douglas J.} and Valentea, {Susana T.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1128/AAC.02574-15",
language = "English (US)",
volume = "60",
pages = "2195--2208",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Ebselen, a small-molecule capsid inhibitor of HIV-1 replication

AU - Thenin-Houssier, Suzie

AU - De Vera, Ian Mitchelle S

AU - Pedro-Rosa, Laura

AU - Brady, Angela

AU - Richard, Audrey

AU - Konnick, Briana

AU - Opp, Silvana

AU - Buffone, Cindy

AU - Fuhrmann, Jakob

AU - Kota, Smitha

AU - Billack, Blase

AU - Pietka-Ottlik, Magdalena

AU - Tellinghuisen, Timothy

AU - Choe, Hyeryun

AU - Spicer, Timothy

AU - Scampavia, Louis

AU - Diaz-Griffero, Felipe

AU - Kojetin, Douglas J.

AU - Valentea, Susana T.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The human immunodeficiency virus type 1 (HIV-1) capsid plays crucial roles in HIV-1 replication and thus represents an excellent drug target. We developed a high-throughput screening method based on a time-resolved fluorescence resonance energy transfer (HTS-TR-FRET) assay, using the C-terminal domain (CTD) of HIV-1 capsid to identify inhibitors of capsid dimerization. This assay was used to screen a library of pharmacologically active compounds, composed of 1,280 in vivo-active drugs, and identified ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one], an organoselenium compound, as an inhibitor of HIV-1 capsid CTD dimerization. Nuclear magnetic resonance (NMR) spectroscopic analysis confirmed the direct interaction of ebselen with the HIV-1 capsid CTD and dimer dissociation when ebselen is in 2-fold molar excess. Electrospray ionization mass spectrometry revealed that ebselen covalently binds the HIV-1 capsid CTD, likely via a selenylsulfide linkage with Cys198 and Cys218. This compound presents anti-HIV activity in single and multiple rounds of infection in permissive cell lines as well as in primary peripheral blood mononuclear cells. Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. This compound also blocks infection of other retroviruses, such as Moloney murine leukemia virus and simian immunodeficiency virus, but displays no inhibitory activity against hepatitis C and influenza viruses. This study reports the use of TR-FRET screening to successfully identify a novel capsid inhibitor, ebselen, validating HIV-1 capsid as a promising target for drug development.

AB - The human immunodeficiency virus type 1 (HIV-1) capsid plays crucial roles in HIV-1 replication and thus represents an excellent drug target. We developed a high-throughput screening method based on a time-resolved fluorescence resonance energy transfer (HTS-TR-FRET) assay, using the C-terminal domain (CTD) of HIV-1 capsid to identify inhibitors of capsid dimerization. This assay was used to screen a library of pharmacologically active compounds, composed of 1,280 in vivo-active drugs, and identified ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one], an organoselenium compound, as an inhibitor of HIV-1 capsid CTD dimerization. Nuclear magnetic resonance (NMR) spectroscopic analysis confirmed the direct interaction of ebselen with the HIV-1 capsid CTD and dimer dissociation when ebselen is in 2-fold molar excess. Electrospray ionization mass spectrometry revealed that ebselen covalently binds the HIV-1 capsid CTD, likely via a selenylsulfide linkage with Cys198 and Cys218. This compound presents anti-HIV activity in single and multiple rounds of infection in permissive cell lines as well as in primary peripheral blood mononuclear cells. Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. This compound also blocks infection of other retroviruses, such as Moloney murine leukemia virus and simian immunodeficiency virus, but displays no inhibitory activity against hepatitis C and influenza viruses. This study reports the use of TR-FRET screening to successfully identify a novel capsid inhibitor, ebselen, validating HIV-1 capsid as a promising target for drug development.

UR - http://www.scopus.com/inward/record.url?scp=84963763473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963763473&partnerID=8YFLogxK

U2 - 10.1128/AAC.02574-15

DO - 10.1128/AAC.02574-15

M3 - Article

C2 - 26810656

AN - SCOPUS:84963763473

VL - 60

SP - 2195

EP - 2208

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -